# Numerate

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/numerate

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Total disclosed funding: $15M
- Latest round: Series A (May 23, 2014)
- Investors on record: 4

## About

Based in California, US, and founded in 2007 by CEO Guido Lanza, Numerate, Inc. operates as a developer of an AI-based drug engineering platform that is used to design and develop small-molecule therapeutics for accelerating immuno-oncology, regenerative medicine, and the treatment of various diseases like Alzheimer’s and metabolic diseases. In November 2019, Valo Health, Inc., a portfolio company of Koch Disruptive Technologies, Longevity Vision Holding, Mirae Asset Capital, Atinum Investment, Invus, HBM Partners, Public Sector Pension Investment Board, and Flagship Pioneering, acquired Numerate, Inc. from Foundation Capital, Lanza Tech Ventures, Atlas Venture, Lilly Ventures, and The National Heart, Lung, and Blood Institute.

 Numerate, Inc. developed a cloud-based AI platform designed for small-molecule drug discovery. This platform enabled data-driven decisions throughout the drug development lifecycle, from hit identification to lead optimization and candidate selection. It was capable of modeling biological systems with limited, noisy, or biased data and featured predictive models for ADME/Tox and protein target interaction. The company focuses on various therapeutic areas such as neurodegeneration, oncology, and cardiovascular disease, supporting both internal programs and strategic external collaborations.

## Funding rounds

- Series A, May 23, 2014, $8.2M — Atlas Venture, Lilly Ventures
- Series B, Feb 18, 2009, $5.5M — Foundation Capital, Lanza Tech Ventures
- Series A, Oct 22, 2008, $1.4M — Foundation Capital, Lanza Tech Ventures

## Investors

- Foundation Capital (https://capitalatlas.ai/funds/foundation-capital) — Series A, Series B
- Lanza Tech Ventures (https://capitalatlas.ai/funds/lanza-tech-ventures) — Series A, Series B
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A